Skip to content

Polymorphism of matrix metalloproteinase gene in patients with cerebral infarction

Polymorphism of matrix metalloproteinase gene in patients with cerebral infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016709
Enrollment
Unknown
Registered
2018-06-20
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

cerebral infarction:none
control group:none

Sponsors

Frist Affiliated Longyan Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Cerebral infarction group: Hospitalized new or recurrent cerebral infarction patients within 48 hours of onset of the disease, who were diagnosed by skull CT and MRI examination, using TOAST classification of cerebral infarction etiological classification, only select the atherosclerosis type and Small artery occlusion type cerebral infarction patients. Control group: Normal people accepting physical examination in the medical center of our hospital during the same period, who no history of cerebrovascular disease and family history of cerebrovascular disease and no genetic history. People in control group have to have no blood relationship between the cerebral infarction group patients, and matched on gender and age each other.

Exclusion criteria

Exclusion criteria: 1) According to TOAST classification, other causes of cerebral infarction besides atherosclerosis and occlusion of small arteries; 2) Combined with severe organ failure (cardiac liver and kidney failure); 3) Combined severe respiratory infection Patients with other organs infected; 4) Patients with moderate or moderate anemia or coagulopathy or other severe hematological diseases; 5) Patients with severe endocrine diseases; 6) Patients with autoimmune system diseases; Cancer patients; 8) Reluctance to participate in the project.

Design outcomes

Primary

MeasureTime frame
MMP-1:rs1799750(-1607 1G/2G);MMP-2:rs243865(-1306C/T);MMP-2: rs2285053 (-735 C>T);MMP-2: rs2241145;MMP-3: rs3025058;MMP-3:rs520540;MMP-3:rs602128;MMP-3:rs679620;MMP-9:rs17576;MMP-12:rs660599;MMP-12:rs2276109;MMP-12:rs652438;

Countries

China

Contacts

Public ContactFan Daofeng

Frist Affiliated Longyan Hospital of Fujian Medical University

290053109@qq.com+86 13616913803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026